Your Article Summary
See Latest ArticlesPharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest
The European Journal of Contraception & Reproductive Health Care, 06/30/09
Zeun S et al. - Treatment with an OC containing E2V and DNG was well tolerated and was associated with stable E2 concentrations over 28 days. The pharmacokinetics of DNG were consistent with previous findings. Minimum serum concentrations of DNG increased only slightly during phases of the regimen during which DNG was administered.
Related Articles
A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis
International Journal of Gynecology & Obstetrics, 10/13/09
Relevance Score: 83%
Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
Contraception, 10/16/09
Relevance Score: 80%
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action
Clinical Pharmacokinetics, 12/18/09
Semi-Mechanistic Population Pharmacokinetic Drug-Drug Interaction Modelling of a Long Half-Life Substrate and Itraconazole
Clinical Pharmacokinetics, 12/18/09
Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome
Current Medical Research and Opinion, 12/17/09